IRON (Disc Medicine) 5-Year EBITDA Growth Rate: 25.60% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IRON Disc Medicine Inc IRON
35 GF Score
Price $79.78
! 3 Warning Signs
View Full Analysis

What is Disc Medicine 5-Year EBITDA Growth Rate?

Disc Medicine IRON +1.17% 35 5-Year EBITDA Growth Rate is 25.60% as of Jun. 2026. GuruFocus rates IRON with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Disc Medicine's EBITDA per Share for the three months ended in Jun. 2026 was $-1.51.

During the past 3 years, the average EBITDA Per Share Growth Rate was 49.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 25.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Disc Medicine was 51.90% per year. The lowest was 22.80% per year. And the median was 49.50% per year.

Disc Medicine  (NAS:IRON) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Disc Medicine 5-Year EBITDA Growth Rate Related Terms

IRON vs CLDX, MBX, QURE: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Disc Medicine's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Disc Medicine 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Disc Medicine's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Disc Medicine's 5-Year EBITDA Growth Rate falls into.


IRON
35GF Score
Disc Medicine Inc IRON
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Disc Medicine 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 25.60% mean?
Disc Medicine (IRON) has a 5-Year EBITDA Growth Rate of 25.60% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Disc Medicine and its competitors.
Is Disc Medicine's 5-Year EBITDA Growth Rate too high?
Disc Medicine's current 5-Year EBITDA Growth Rate is 25.60%. Overall, Disc Medicine has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Disc Medicine's 5-Year EBITDA Growth Rate compare to CLDX and MBX?
Disc Medicine's 5-Year EBITDA Growth Rate of 25.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Disc Medicine and its competitors. Disc Medicine's current 5-Year EBITDA Growth Rate is 25.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Disc Medicine stock overvalued right now?
Disc Medicine (IRON) has a current 5-Year EBITDA Growth Rate of 25.60%. The current 5-Year EBITDA Growth Rate is 25.60%. Disc Medicine's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Disc Medicine (IRON), the current 5-Year EBITDA Growth Rate is 25.60% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Disc Medicine Business Description

Address 321 Arsenal Street, Suite 101, Watertown, MA, USA, 02472
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
35GF Score

Get the complete analysis for IRON

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.78
Price